ValuEngine downgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a buy rating to a hold rating in a report released on Monday morning.
Several other brokerages have also recently commented on PAHC. BidaskClub cut shares of Phibro Animal Health from a buy rating to a hold rating in a research report on Thursday, August 16th. Zacks Investment Research cut shares of Phibro Animal Health from a hold rating to a strong sell rating in a research report on Wednesday, October 24th. Finally, Morgan Stanley boosted their target price on shares of Phibro Animal Health from $36.00 to $46.00 and gave the company an underweight rating in a research report on Wednesday, August 29th. Four equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. Phibro Animal Health presently has an average rating of Sell and an average target price of $43.50.
Phibro Animal Health stock traded down $0.17 during midday trading on Monday, hitting $35.88. The company’s stock had a trading volume of 13,789 shares, compared to its average volume of 113,114. Phibro Animal Health has a 1-year low of $32.05 and a 1-year high of $54.62. The company has a quick ratio of 1.82, a current ratio of 3.26 and a debt-to-equity ratio of 1.62. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 20.62, a price-to-earnings-growth ratio of 3.02 and a beta of 0.82.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 19th. Stockholders of record on Wednesday, November 28th will be given a $0.12 dividend. The ex-dividend date of this dividend is Tuesday, November 27th. This is a boost from Phibro Animal Health’s previous quarterly dividend of $0.10. This represents a $0.48 annualized dividend and a dividend yield of 1.34%. Phibro Animal Health’s payout ratio is presently 22.99%.
In related news, insider Jack Bendheim sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The shares were sold at an average price of $50.04, for a total transaction of $1,501,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dean J. Warras sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $42.84, for a total transaction of $428,400.00. Following the transaction, the insider now owns 10,000 shares of the company’s stock, valued at $428,400. The disclosure for this sale can be found here. Insiders sold a total of 93,020 shares of company stock valued at $4,481,471 over the last 90 days. Corporate insiders own 50.29% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new position in Phibro Animal Health during the 3rd quarter worth approximately $115,000. Royal Bank of Canada grew its holdings in Phibro Animal Health by 2,104.6% during the 1st quarter. Royal Bank of Canada now owns 3,814 shares of the company’s stock worth $151,000 after acquiring an additional 3,641 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in Phibro Animal Health by 149.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 4,470 shares of the company’s stock worth $206,000 after acquiring an additional 2,676 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Phibro Animal Health during the 3rd quarter worth approximately $206,000. Finally, Piedmont Investment Advisors LLC bought a new stake in Phibro Animal Health during the 2nd quarter worth approximately $213,000. Institutional investors and hedge funds own 48.25% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Recommended Story: What are retained earnings?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.